ClinicalTrials.gg
CompletedNCT07228949Updated Oct 8, 2026

Complex Regional Pain Syndrome: Analgesic Outcome

An observational study in Chronic Pain and Complex Regional Pain Syndrome, sponsored by Ciusss de L'Est de l'Île de Montréal. Completed at 2 sites in Canada. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Ciusss de L'Est de l'Île de Montréal · Observational

How we know

Updated Oct 8, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
201
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 202 studies in Chronic Pain with a site in Canada — 52 open to participants now, 62 under way, 4 of them phase 3. Chronic Pain · Canada.

Enrollment
17th of 40
201 · median 138
Started
2025
with 18 others
Observational
40 of 202
12 open now
Registered
191st of 202
by date
Lead sponsor
6 of 202
Ciusss de L'Est de l'Île de Montréal

Among the 202 studies in Chronic Pain with a site in Canada, this one is the 17th largest by enrollment of the 40 observational ones that give a count, is one of 19 that started in 2025, is one of 40 observational ones, and was the 191st registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

52 of the 202 studies in Chronic Pain with a site in Canada are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Chronic Pain with a site in Canada, or all of them as a file.
02

Study summary

This retrospective observational study aims to describe the use and analyze the effectiveness of various analgesic interventions in patients diagnosed with Complex Regional Pain Syndrome (CRPS) at the Pain Management Center of Hôpital Maisonneuve-Rosemont (HMR) between January 2020 and October 2025.

Background:

Complex Regional Pain Syndrome is a chronic pain condition characterized by severe, persistent pain accompanied by sensory, vasomotor, sudomotor, and motor/trophic changes, often following trauma or surgery. Despite established diagnostic criteria (Budapest criteria), its pathophysiology remains poorly understood, and evidence-based treatments are limited. While multidisciplinary functional rehabilitation remains the cornerstone of management, various analgesic interventions are used to facilitate recovery when medications fail to adequately control pain.

Common interventions include:

  • Plexus or peripheral nerve blocks (brachial or sciatic, with or without adjuvants such as dexamethasone or dexmedetomidine)
  • Intravenous ketamine infusions
  • Sympathetic blocks (stellate or lumbar)
  • Intravenous pamidronate infusions

Although all these techniques are used in clinical practice, their relative efficacy and predictive factors for success remain unknown. Clinicians rely on experience rather than data-driven guidance to select an initial intervention. Identifying factors such as CRPS subtype or symptom duration that predict analgesic response could improve treatment efficiency and functional recovery.

Methods:

This is a retrospective chart review including all adult patients with a CRPS diagnosis established using the Budapest criteria who received at least one eligible analgesic intervention during the study period. Data will be extracted from electronic medical records by the research team. Exclusion criteria include incomplete clinical documentation or missing information regarding the first consultation, intervention type, or analgesic outcome.

Collected variables include demographics, medications, CNESST (workers' compensation) status, PTSD diagnosis, trauma type, CRPS characteristics (affected limb, type, subtype, symptom duration), details of the first intervention (technique, dose, use of adjuvants), analgesic response, and adverse effects.

Read the detailed description

STUDY MODEL Retrospective observational study in the form of a chart review. STUDIED POPULATION AND PERIOD Patients followed at the Maisonneuve-Rosemont Hospital Pain Management Center (PMC) for complex regional pain syndrome (CRPS) who received at least one analgesic intervention between January 1, 2020 and October 2025.

This period was chosen to obtain a sufficient number of patients and to best reflect current practice.

SAMPLE SIZE A sample size calculation will not be performed for this study. The PMC is a tertiary pain clinic that treats a large number of patients, and it is estimated that the chosen period will yield a sample of approximately 200 patients.

GENERAL PROCEDURE Data will be collected from digitized records in the Clinibase and Oacis clinical applications.

An initial sampling of charts will be performed in Clinibase by the planning, programming, and research department of the CIUSSS de l'Est-de-l'Île-de-Montréal. A search of the Clinibase database using the type of appointment at the Pain Management Center between January 1, 2020, and October 23, 2025, will provide the chart numbers of potentially eligible patients. The appointment types searched will include: block, ketamine infusion, pamidronate, stellate block, and lumbar sympathetic block.

Each chart will then be reviewed in Oacis to locate the first consultation note at the Pain Management Center in order to verify inclusion criteria-specifically, a diagnosis of complex regional pain syndrome as determined by the Budapest criteria. The use of an eligible analgesic intervention (plexus block, pamidronate infusion, ketamine infusion, stellate or lumbar sympathetic block) for the treatment of CRPS pain will be confirmed. The analgesic technique does not necessarily need to have been performed at the first visit to be eligible. Charts meeting the inclusion criteria will be retained for the research project and analyzed in more detail to collect the required data.

DATA COLLECTION

Patient data:

  • Demographic data

    • Age
    • Sex
  • Association of the chart with a worker's compensation agency (CNESST in Quebec) (yes/no) (This information will be collected because affiliation with a workers' compensation program is an independent factor for poorer response to analgesic interventions. It is therefore a confounding factor for the primary endpoint-intervention success) (Clin J Pain 1995;11:94-102);
  • Patient's medication (SSRI antidepressants (yes/no), tricyclic antidepressants (yes/no), gabapentinoids (yes/no), NSAIDs (yes/no), opioids (yes/no))
  • Initial trauma (fracture, sprain, surgery, stroke, other);
  • Post-traumatic stress disorder (yes/no). This variable will be collected for the same reason as CNESST affiliation. A PTSD diagnosis significantly affects pain intensity and treatment response, particularly if inadequately addressed (J Pain Res 2018;11:527-36).

CRPS data:

  • Upper or lower limb involvement;
  • Left or right;
  • Duration of symptoms at the time of first analgesic intervention (measured from the initiating event) (\<12 months, 12-18 months, >18 months);
  • Symptoms reported by the patient:

    • Sensory: hyperalgesia (yes/no), allodynia (yes/no)
    • Vasomotor: temperature asymmetry (yes/no), color asymmetry (yes/no), skin color change (yes/no)
    • Sudomotor: edema (yes/no), sweating change (yes/no)
    • Motor/trophic: decreased range of motion (yes/no), tremor (yes/no), weakness (yes/no), dystonia (yes/no), trophic changes in skin, nails and/or hair (yes/no).
  • Signs observed by the physician:

    • Sensory: hyperalgesia (yes/no), allodynia (yes/no)
    • Vasomotor: temperature asymmetry (yes/no), color asymmetry (yes/no), skin color change (yes/no)
    • Sudomotor: edema (yes/no), sweating change (yes/no)
    • Motor/trophic: decreased range of motion (yes/no), tremor (yes/no), weakness (yes/no), dystonia (yes/no), trophic changes in skin, nails and/or hair (yes/no).
  • CRPS category (type I, type II, ROS, NOS)
  • CRPS subtype, as determined by the main symptom reported at the first consultation:

    • Vasomotor: predominance of vasomotor and sudomotor signs/symptoms
    • Sensory: predominance of sensory signs/symptoms (hyperalgesia, allodynia)
    • Florid: most symptoms present and/or motor symptoms predominant
    • Undetermined (chart notes do not allow subtype determination)

First intervention performed:

  • Plexus block

    • Infraclavicular, axillary, interscalene, popliteal sciatic
    • Dose of agent used (mL)
    • Adjuvant (yes/no)
    • Type of adjuvant: dexamethasone (yes/no), dexmedetomidine (yes/no)
  • Sympathetic block

    • Stellate, lumbar
    • Ultrasound-guided (yes/no), fluoroscopy (yes/no), anatomical landmarks (yes/no)
    • Dose of agent used (mL)
  • Ketamine infusion

    • Dose (mg)
    • Duration (min)
    • Concomitant use of midazolam (yes/no) If yes, dose (mg)
  • Pamidronate infusion o Dose (mg)

Follow-up visit data:

  • Analgesic success (yes/no), defined as significant pain reduction that allowed improved function, according to patient report.
  • Report of adverse effects (yes/no)
  • Type of adverse effect reported: pain increase, severe pain at puncture site, hematoma, infection, nausea/vomiting, nightmares, general malaise, other)

Data from other follow-up visits:

  • Number of different analgesic interventions required to achieve significant relief: 1, 2, 3, 4, or no analgesia
  • Type of intervention that was beneficial (if the first intervention did not provide relief) STATISTICAL ANALYSES Data will be stored in an Excel file and analyzed with SPSS Statistics software. Continuous data will be analyzed using the Shapiro-Wilk test to assess normality. Normally and non-normally distributed values will be reported as mean (standard deviation) and median (interquartile range), respectively. Categorical data will be reported as number (percentage). The primary objective-the frequency distribution of first-line analgesic interventions-will be reported as number (percentage), as will the analgesic success rate for each intervention. The success rate of each technique by CRPS subtype and symptom duration will then be analyzed using the Chi-square or Fisher's exact test. A p \< 0.05 will be considered statistically significant.

To better compare the different techniques, a propensity score approach will be used. The probability of receiving each treatment will be calculated based on the following characteristics: age, sex, symptom duration, limb type, CNESST affiliation, medications used, treating physician, and CRPS subgroup. These probabilities will be calculated using multinomial logistic regression and will define the propensity scores. Each patient's characteristics will be weighted using the Inverse Probability of Treatment Weighting (IPTW) method. After weighting, group balance will be verified by ensuring that standardized mean differences (SMD) for each covariate are below 0.1. Finally, the weighted success rate for each technique will be calculated. Weighted Odds Ratios (OR) with 95% confidence intervals will also be computed using weighted logistic regression for each treatment compared to the reference treatment. Sensitivity analyses will be performed using other weighting methods such as Overlap Weighting, 1:1 Matching, and Entropy Balancing.

To identify the best treatment for each subgroup, the probability of success as a function of treatment, subgroup, and a "treatment × subgroup" interaction term will be calculated using logistic regression. If the interaction term is significantly associated with the probability of success, stratified analyses will be conducted by subgroup. For each subgroup, a propensity score will be calculated using the same method described above, excluding the subgroup variable from adjustment. Weighted success probabilities will be calculated for each treatment and each subgroup, as well as ORs with 95% CIs compared to the reference treatment, to identify the optimal treatment for each subgroup.

03

Conditions studied

  • Chronic Pain
  • Complex Regional Pain Syndrome

Keywords

  • Chronic Pain
  • complex regional pain syndrome
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients treated at HMR's Pain management centre for CRPS between January 1st 2020 and October 2025.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of complexe regional pain syndrome
  • Patients who received at least one of the following intervention: peripheral nerve block (infraclavicular, intrerscalene, axillary, popliteal sciatic), sympathetic block (stellate, lumbar), intravenous ketamine infusion, or intravenous pamidronate infusion)

Exclusion criteria

Exclusion Criteria:

  • First consultation is not digitalized
  • Information on signs and symptoms at the first consultation is missing
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
201 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients who received at least one eligible analgesic intervention

    Patient's treated at Maisonneuve-Rosemont Hospital Pain Management Centre for complex regional pain syndrome between January 2020 and October 2025 who received at least one eligible analgesic intervention (plexus or peripheral nerve block, sympathetic block, IV Ketamine infusion, IV Pamidronate infusion)

06

What researchers measure

Primary outcomes

  1. Frequency distribution of first-line analgesic interventions

    To determine the frequency distribution of first-line analgesic interventions used in patients with complex regional pain syndrome

    Time frame: within 6 months of first visit at the Pain Clinic

07

Study locations

2 sites
  • Maisonneuve-Rosemont Hospital
    Montreal, Quebec H1T2M4, Canada
  • Hopital Maisonneuve Rosemont
    Montreal, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in May 2026, 5 months.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → May 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 14, 2025
StartActual
Nov 15, 2025
Primary completionActual
May 1, 2026was Jun 2026
CompletionActual
Jun 1, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 8, 2026
Primary completion
Jun 2026→May 1, 2026 (actual)
Oct 8, 2026
Enrollment
200 (estimated)→201 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Active, not recruiting→Completed
    Primary completion Jun 2026→May 1, 2026 (now actual)
    Enrollment 200 (estimated)→201 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07228949
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Responsible party
Veronique Brulotte (Doctor, Ciusss de L'Est de l'Île de Montréal) — Principal investigator
First posted
Nov 14, 2025
Start date
Nov 15, 2025
Primary completion
May 1, 2026
Completion
Jun 1, 2026
Last update
Oct 8, 2026

Study contacts

Veronique Brulotte, MD
principal investigator · CIUSSS-de-l'Est-de-l'Ile-de-Montréal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion